Profile data is unavailable for this security.
About the company
BSF Enterprise PLC is a United Kingdom-based biotech company. The Company is focused on developing biotechnological solutions using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes. The Company operates through its wholly owned subsidiary, 3D Bio-Tissues Limited (3DBT), which is a clinical and cellular agriculture company engaged in producing human corneas that could help restore vision to millions of people. 3DBT has three strands of three intellectual property (IP) each with a different sector focus development and revenue timeline. 3DBT’s City-mix is an animal-free cell growth agent for culturing skin, muscle and fat cells which are used for lab-grown meat and leather production. 3DBT’s Lipopeptide Etsyl actively increases collagen production in human skin cells which can be used in cosmetic and skin care products.
- Revenue in GBP (TTM)67.24k
- Net income in GBP-1.71m
- Incorporated2018
- Employees4.00
- LocationBSF Enterprise PLCGround Floor, 31 Old Burlington StreetLONDON W1S 3ASUnited KingdomGBR
- Phone+44 203 283 4590
- Websitehttps://bsfenterprise.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nuformix PLC | 0.00 | -341.86k | 709.65k | 2.00 | -- | 0.0999 | -- | -- | -0.0005 | -0.0005 | 0.00 | 0.005 | 0.00 | -- | -- | -- | -7.72 | -- | -8.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| CRISM' Therapeutics Corp | 0.00 | -349.70k | 3.10m | 4.00 | -- | 1.50 | -- | -- | -0.0408 | -0.0408 | 0.00 | 0.0634 | 0.00 | -- | -- | 0.00 | -8.18 | -8.91 | -12.38 | -9.27 | -- | -- | -- | -- | -- | -1.01 | 0.00 | -- | -- | -- | 9.04 | -- | -- | -- |
| BSF Enterprise PLC | 67.24k | -1.71m | 3.36m | 4.00 | -- | 0.8408 | -- | 49.95 | -0.0166 | -0.0166 | 0.0007 | 0.0387 | 0.0128 | 1.79 | 0.0425 | 16,810.00 | -32.47 | -- | -34.78 | -- | -44.74 | -- | -2,542.56 | -- | 6.17 | -218.85 | 0.0287 | -- | -- | -- | -61.40 | -- | -- | -- |
| Oxford Biodynamics PLC | 617.00k | -11.11m | 3.84m | 45.00 | -- | 1.52 | -- | 6.22 | -0.0643 | -0.0643 | 0.0035 | 0.008 | 0.0487 | 1.20 | 0.379 | 13,711.11 | -87.64 | -39.72 | -114.28 | -45.52 | 41.49 | -- | -1,800.32 | -1,324.62 | 0.6156 | -87.72 | 0.7873 | -- | 231.17 | -15.53 | -61.34 | -- | -1.60 | -- |
| Kanabo Group PLC | 1.14m | -8.18m | 6.32m | 17.00 | -- | 1.07 | -- | 5.55 | -0.013 | -0.013 | 0.0018 | 0.0094 | 0.1054 | 16.28 | 43.85 | 67,058.82 | -75.70 | -75.83 | -81.16 | -83.33 | 7.89 | -- | -718.33 | -1,267.35 | 2.72 | -63.43 | 0.0337 | -- | 48.42 | -- | -16.26 | -- | -- | -- |
